Caterina Marchiò, MD, PhD explains the benefits of performing in-house CGP testing vs test send-out to increase the opportunities for precision medicine for cancer patients. Dr. Marchiò presents 3 patient cases for whom CGP detected unexpected genomic alterations leading to accurate diagnosis and biomarker-driven therapy. Caterina Marchiò MD, PhD is a professor of pathology at the Candiolo Cancer Institute, University of Turin, Italy. Share this video in Italian: https://youtu.be/rwqJIGmddVA Learn about in-house CGP including homologous recombination deficiency (HRD): https://youtu.be/qz9auYRPvV8 Learn more about finding rare mutations: https://youtu.be/pDN8InXWx3I?si=l5gsnqDXPiPopBdQ Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM LinkedIn: https://www.linkedin.com/company/illumina X: https://x.com/illumina Instagram: https://www.instagram.com/illuminainc/ Facebook: https://www.facebook.com/illuminainc TikTok: https://www.tiktok.com/@illuminainc #CGP #TumorBiomarker #Illumina